| Identifier |
20240303_nanos_posters_131 |
| Title |
Satralizumab Treatment In Adults With AQP4-IgG- Seropositive Neuromyelitis Optica Spectrum Disorder: A Retrospective Case Series |
| Creator |
Hesham Abboud; Brian Steingo; Diana Vargas; Julie Patel; Nancy Nealon; Mary Alissa Willis; Yang Mao-Draayer; Dmitry Khaitov; Jose Avila Ornelas; Adnan Subei; Clifford Reed; William S. Baek; Michelle Tsai; Angie Kim; Ahmed Z. Obeidat; Krupa Pandey; Michael Levy; Negar Molazadeh; Robert K. Shin; Rebecca S. Romero; Paige Goulette; Rosemarie Walch; Jeanie Coté; Robert Pace; Buse Sengul; Lisa Ferayorni; Shervin Gholizad |
| Affiliation |
(HA) University Hospitals Cleveland Medical Center; (BS) Infinity Clinical Research; (DV) Emory University School of Medicine; (JP) Emory University School of Medicine and Emory University Hospital Midtown; (NN) Weill Cornell Medicine; (MAW) University of Mississippi Medical Center; (YM) Michigan Institute for Neurological Disorders; (DK) Lehigh Valley Health Network; (JAO) HIMA Caguas Multiple Sclerosis Center; (AS) Neurology Consultants of Dallas; (CR) Reading Hospital; (WSB) Parkside Medical Group; (MT) Ochsner Health System; (AK) NYU Langone Health and NYU Grossman School of Medicine; (AZO) Medical College of Wisconsin; (KP) Hackensack University Medical Center, Hackensack Meridian School of Medicine; (ML) Massachusetts General Hospital and Harvard Medical School; (RKS) MedStar Georgetown University Hospital; (RSR) University of Texas Health Science Center at San Antonio; (PG) (RW) (JC) (RP) (BS) Memorial Healthcare; (LF) (SG) Genentech, Inc. |
| Subject |
Neuro-ophth & Systemic Disease ( eg. MS, MG, thyroid); Optic Neuritis; Demeylinating Disease |
| Description |
Neuromyelitis optica spectrum disorder (NMOSD is a rare autoimmune neuroinflammatory disease that primarily affects the optic nerves and spinal cord and can lead to sensory/motor impairment, vision loss and permanent neurological disability. The US Food and Drug Administration approved satralizumab for use in adults with aquaporin 4 autoantibody-positive (AQP4-IgG+) NMOSD in 2020, but real-world data are limited. We describe the experience with satralizumab in adults with AQP4-IgG+ NMOSD in clinical practice. |
| Date |
2024-03 |
| References |
None provided. |
| Language |
eng |
| Format |
application/pdf |
| Type |
Text |
| Source |
2024 North American Neuro-Ophthalmology Society Annual Meeting |
| Relation is Part of |
NANOS Annual Meeting 2024: Poster Session: Descriptive Studies I: Neuro-Ophthalmic Disorders of Neurologic and Systemic Diseases |
| Collection |
Neuro-Ophthalmology Virtual Education Library: NANOS Annual Meeting Collection: https://novel.utah.edu/collection/nanos-annual-meeting-collection/ |
| Publisher |
North American Neuro-Ophthalmology Society |
| Holding Institution |
Spencer S. Eccles Health Sciences Library, University of Utah |
| Rights Management |
Copyright 2024. For further information regarding the rights to this collection, please visit: https://NOVEL.utah.edu/about/copyright |
| ARK |
ark:/87278/s6ts8n93 |
| Setname |
ehsl_novel_nam |
| ID |
2593971 |
| Reference URL |
https://collections.lib.utah.edu/ark:/87278/s6ts8n93 |
